STUDY OF LIPID PROFILE IN HIV/AIDS PATIENTS ON ANTIRETROVIRAL THERAPY

Abstract

The introduction of effective highly active antiretroviral therapy(HAART) in the mid 1990s led to a marked reduction in the morbidity and mortality of HIV infection. Side effects of HAART such as dyslipidemia were soon described after its introduction. It becomes very important to identify dyslipidemia in HIV patients on antiretroviral therapy for the early detection and prevention of premature coronary vascular events in such patients.